. 2020 Apr 1;27(Suppl 2):S87–S97. doi: 10.3747/co.27.5223

TABLE II.

Agonistic and antagonistic immune checkpoint modulators currently under investigation

Target	Drug	Company	Clinical phase
Costimulatory or agonist antibodies

4-1BB (CD137)	Utomilumab	Pfizer Canada, Kirkland, QC	I
	Urelumab	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II
	INBRX-105	Inhibrx, San Diego, CA, U.S.A.	I

ICOS (CD278)	GSK3359609	GlaxoSmithKline, Mississauga, ON	I/II
	JTX-2011	Jounce Therapeutics, Cambridge, MA, U.S.A.	I/II

GITR (CD357)	TRX 518-001	Leap Therapeutics, Cambridge, MA, U.S.A.	I/II
	MK-4166	Merck, Kenilworth, NJ, U.S.A.	I
	BMS-986156	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II
	INCAGN01876	Incyte Biosciences International, Wilmington, DE, U.S.A.	I/II

CD70	ARGX-110 (cusatuzumab)	Argenx, Breda, Netherlands	I/II

CD27	CDX-1127 (varlilumab)	Celldex Therapeutics, Hampton, NJ, U.S.A.	I/II

OX40 (CD134)	PF-0451860	Pfizer Canada, Kirkland, QC	I/II
	MEDI0562/6469/6383	AstraZeneca Canada, Mississauga, ON	I
	GSK3174998	GlaxoSmithKline, Mississauga, ON	I
	BMS-986178	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II

CD40	CP870893	Pfizer Canada, Kirkland, QC	I

	APX005M	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II
Co-inhibitory or antagonist antibodies

VISTA (B7-H5)	CA-170	Curis, Lexington, MA, U.S.A.	I

CCR4 (CD194)	Mogamulizumab	Kyowa Kirin, Tokyo, Japan	I/II

B7-H3 (CD276)	MGD009	Novartis Pharmaceutical, Ottawa, ON	I

	8H9	Y-mAbs Therapeutics, New York, NY, U.S.A.	I
TIM-3	TSR-022	Tesaro, Waltham, MA, U.S.A.	I
	MBG453	Novartis Pharmaceutical, Ottawa, ON	I/II
	Sym023	Symphogen A/S, Ballerup, Denmark	I
	MEDI9447 (oleclumab)	AstraZeneca Canada, Mississauga, ON	I

LAG-3 (CD223)	BMS-986016 (relatlimab)	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II
	IMP321 (eftilagimod alpha)	Prima BioMed, Sydney, Australia	II
	LAG525	Novartis Pharmaceutical, Ottawa, ON	I/II

KIR (2DL1–3)	Lirilumab	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II

IDO-1,2	Indoximod	NewLink Genetics, Ames, IA, U.S.A.	II
	Epacadostat	Incyte Biosciences International, Wilmington, DE, U.S.A.	II

TIGIT	Tislelizumab	BeiGene, Beijing, P.R.C.	I/II/III
	BMS-986207	Bristol–Myers Squibb, New York, NY, U.S.A.	I/II
	MTIG7192A	Genentech, San Francisco, CA, U.S.A.	II/III
	AB154	Arcus Biosciences, Hayward, CA, U.S.A.	I/II

A2aR	Ciforadenant	Corvus Pharmaceuticals, Burlingame, CA, U.S.A.	I

Transforming growth factor β	M7824	EMD Serono, Rockland, MA, U.S.A.	I/II
	Galunisertib	Eli Lilly and Company, Indianapolis, IN, U.S.A.	II

CD47	TTI-621	Trillium Therapeutics, Mississauga, ON	I

CD73	MEDI9447 (oleclumab)	AstraZeneca Canada, Mississauga, ON	I
Other pathways

Toll-like receptors	Poly-ICIC	Ludwig Institute for Cancer Research, New York, NY, U.S.A.	I
	MGN1703 (lefitolimod)	Mologen, Berlin, Germany	I
	SD-101	Dynavax Technologies Corporation, Emeryville, CA, U.S.A.	I/II
	DSP-0509	Boston Biomedical, Cambridge, MA, U.S.A.	I/II
	Rintatolimod	Hemispherx Biopharma, Philadelphia, PA, U.S.A.	II
	CMP-001	Checkmate Pharmaceuticals, Cambridge, MA, U.S.A.	II

Interleukin 2 receptor	NKTR-214	Nektar Therapeutics, San Francisco, CA, U.S.A.	I/II/III
	RO6874281	Hoffmann–La Roche, Basel, Switzerland	I/II
	THOR-707	Synthorx, La Jolla, CA, U.S.A.	I/II

Arginase inhibitors	CB-1158	Incyte Corporation, Wilmington, DE, U.S.A.	I/II

Oncolytic peptides	LTX-315	Lytix Biopharma, Oslo, Norway	II

Interleukin 10	AM0010 (pegilodecakin)	Eli Lilly and Company, Indianapolis, IN, U.S.A.	I/II

Poly-ICLC = polyinosinic-polycytidylic acid–poly–L-lysine carboxymethylcellulose.